Brendan D Curti

16PUBLICATIONS
80CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunology not elsewhere classifiedGene and molecular therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 14, 2026
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

|Sep 29, 2025
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial.

Jong Chul Park, Brendan Curti, Marcus Butler

|Jan 03, 2025
Checkpoint Immunotherapy for Melanoma - Offering Hope for Cure.

Brendan D Curti

|Jul 18, 2024
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.

Helen Gogas, Shruthi Ravimohan, Antara Datta

|Aug 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.

Adi Diab, Helen Gogas, Shahneen Sandhu

|Jun 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.

Andrew L Coveler, David C Smith, Tycel Phillips

Pageof 3

Frequent Collaborators

2 joint publications

John M Kirkwood

2 joint publications

Walter J Urba

2 joint publications

Rom S Leidner

2 joint publications

Céleste Lebbé